Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial

Rakesh Popat; Bradley Augustson; Paul Cannell; Keith Stockerl-Goldstein; Amit Khot; Ajay Nooka; N. Patel; Ravi S. Kasinathan; Astrid McKeown; Amy Curry; Mehreen Shaikh; Fernando Carreno; Sumita Roy-Ghanta; J. Opalinska; Hang Quach

doi:10.1158/1078-0432.ccr-25-3216

Related publications

Article2020

DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).

Ajay K. Nooka, Keith Stockerl‐Goldstein, Hang Quach, Adam Forbes, María‐Victoria Mateos, Amit Khot, Alan Tan, Rafat Abonour, Bikramjit Chopra, Rachel Rogers, Geraldine Ferron‐Brady, Jacqueline Davidge, Steve Frey, Anne Yeakey, Mala K. Talekar, Katarina Luptakova, Ira Gupta, Rakesh Popat

Article2023

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Vânia T. M. Hungria, Katja Weisel, Atanas Radinoff, Sosana Delimpasi, Gábor Mikala, Tamás Masszi, Li J, Marcelo Capra, Ângelo Maiolino, Vasiliki Pappa, Dominik Chraniuk, Iurii Osipov, Xavier Leleu, Michael Löw, Morio Matsumoto, Mary Li, Neal Sule, Margaret Polinkovsky, Randy Davis, Shelley Bright, Astrid McKeown, Joanna Opalińska, Meletios A Dimopoulos

Article2020

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Robert M. Rifkin, Kevin Boyd, Sebastian Grosicki, Kihyun Kım, Francesco Di Raimondo, Meletios A Dimopoulos, Katja Weisel, Bertrand Arnulf, Roman Hájek, Vânia T. M. Hungria, Andrew Spencer, Randy Davis, Antonio Riccio, Chanbin Kim, Jodie Wilkes, Ruth Z. Rutledge, Mala K. Talekar, Brandon E. Kremer, Ira Gupta, María‐Victoria Mateos

Article2024

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard LeBlanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Façon, Cesar Rodriguez, Ralph Wäsch, Meletios A Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab

Article2025

Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.

Paula Rodríguez‐Otero, Sosana Delimpasi, Albert Oriol, Meletios A Dimopoulos, Xavier P. Leleu, Salomon Manier, Carmen Martínez‐Chamorro, Rajshekhar Chakraborty, Sam Rubinstein, Anna Sureda, Marta Sonia González, Jean‐Marie Michot, Aurora Breazna, James Drew, Anita Boyapati, Sheila Masinde, Glenn S. Kroog, Shawn Sarkaria, Joaquín Martínez‐López